Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Phillips on the Evolution of MDS Treatment

July 18th 2024

Tycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.

INCB057643 ± Ruxolitinib Shows Early Tolerability, Efficacy in Advanced Myelofibrosis

July 16th 2024

Justin M. Watts, MD, discusses phase 1 efficacy and safety data for the oral BET inhibitor INCB057643 in advanced myelofibrosis.

FDA Places Partial Clinical Hold on Phase 1 Trial of Seclidemstat Plus Azacitidine in MDS/CMML

July 16th 2024

The FDA has placed a partial clinical hold on a trial evaluating seclidemstat plus azacitidine in myelodysplastic syndromes or chronic myelomonocytic leukemia.

Pelabresib/Ruxolitinib Data Underscore Need for Novel End Points in Myelofibrosis Trials

July 15th 2024

Aaron Gerds, MD discusses updated efficacy findings from the prospective randomized phase 3 MANIFEST-2 trial.

Dr Klisovic on the Early Use of JAK Inhibitors in Younger Patients With Low-Risk Myelofibrosis

July 15th 2024

Rebecca Klisovic, MD, discusses the early use of JAK inhibitors to treat younger patients with low-risk, newly diagnosed myelofibrosis.

Dr Sekeres on Outcomes With Imetelstat in Transfusion-Dependent MDS

July 11th 2024

Mikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.

Dr Hunter on the Management Ruxolitinib-Associated AEs in Myelofibrosis

July 11th 2024

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

Observational MOST Trial Reveals Progression Trends in Low-Risk Myelofibrosis

July 11th 2024

Aaron Gerds, MD, discusses progression data for patients with low- or intermediate-1–risk myelofibrosis in the MOST trial.

Subanalysis Supports Imetelstat for Transfusion-Dependent Low- to Intermediate-1–Risk MDS

July 10th 2024

Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.

Phillips Discusses Past Progress and Previews the Future in Hematologic Cancers

July 10th 2024

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Dr Hunter on the Evolution of Pathology in Myelofibrosis

July 2nd 2024

Anthony M. Hunter, MD, discusses the evolution of pathology in myelofibrosis based on outcomes from clinical trials.

Dr Sekeres on Outcomes from the ASTREON Trial in Low- to Intermediate-Risk MDS

June 26th 2024

Mikkael A. Sekeres, MD, discusses preliminary outcomes with oral azacitidine in lower-risk myelodysplastic syndromes, as reported in the ASTREON trial.

Momelotinib Wins Japanese Approval for Myelofibrosis

June 24th 2024

The Ministry of Health, Labour, and Welfare in Japan has approved momelotinib for use in patients with myelofibrosis.

Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis

June 21st 2024

This is safety and efﬁcacy update on the MANIFEST-2 trial (NCT02158858), a global, randomized, double-blind, active-control, phase 3 study using pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myeloﬁbrosis.

Dr Gerds on the Clinical Implications of Pelabresib Plus Ruxolitinib in Myelofibrosis

June 14th 2024

Aaron Gerds, MD, discusses the clinical implications of outcomes with pelabresib plus ruxolitinib therapy in JAK inhibitor–naive myelofibrosis.

Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis

June 14th 2024

Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.

Observational Study Finds Progression Common in Lower-Risk Myelofibrosis

June 14th 2024

Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.

Dr Watts on the Safety of the BET Inhibitor INCB057643 in Myelofibrosis

June 11th 2024

Justin M. Watts, MD, discusses the safety profile and tolerability of INCB057643 in patients with myelofibrosis.

Factors for JAK Inhibitor Selection in Myelofibrosis in the First Line and Beyond

June 9th 2024

Anthony Hunter, MD, discusses JAK inhibitor selection in myelofibrosis in the first line and beyond.